Ovarian Cancer
Conditions
Keywords
immunotherapy, ovarian cancer, durvalumab, tremelilumab, MEDI 9447, MEDI 0562
Brief summary
The overall objectiv is to obtain preliminary evidence of efficacy of novel agents for the management of relapsed ovarian cancer, and in part 2 efficacy of novel agents compared to the standard of care (SoC).
Interventions
DRUGDurvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Three different combination are being tested. Each cohort has different combination
Sponsors
Gynecologic Cancer Intergroup (GCIG)
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Part 1: single cohorts of novel agents Part 2: randomized phase 2 against standard of care.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Platinum-sensitive disease: defined as disease progression ≥ 6 months following the last administered dose of platinum-based therapy. Patients must have received atleast one line of chemotherapy for platinum-sensitive disease. OR 2. Platinum-resistant disease: defined as disease progression \< 6 months following the last administered dose of platinum-based therapy. OR 3. Platinum-refractory disease: defined as lack of response or disease progression while receiving the most recent therapy. Other key inclusion criteria: 4. Histological confirmed ovarian, fallopian tube or peritoneal cancers. 5. Histological types: high-grade serious, high-grade endometriod, undifferentiated, carcinosarcoma or mixed histology. 6. Subjects must have at least 1 measurable lesion as defined by RECIST guidelines. This should not be the same lesion used for biopsy. 7. Patients entering cohort A: Archival tumour tissue must be screened for CD73 and only CD73 positive patients (defined as \>10% of tumor cells positive) will enter this trial. 8. Patient agrees to undergo all analysis (blood, serum, tissue); radiological examinations according to protocol. 9. Mandatory tumour biopsy before treatment (before day 0) and at day 56 of treatment. 10. Patients must give informed consent. 11. Patients must be at least 18 years of age. 12. ECOG performance status 0-1 13. Serum albumin \>30g/l. 14. Adequate organ function 15. Life expectancy of at least 12 weeks. 16. Patients must be fit to receive Investigational medical products (IMPs)
Exclusion criteria
1. Subjects using immunosuppressive medications within 14 days. 2. Immunodeficiency or organ transplant 3. Live vaccines within 28 days prior to the first dose. 4. Major surgery within 28 days prior to the first dose. 5. Ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial can-cers. 6. Cancer therapies (chemotherapy, radiotherapy, surgery, immunotherapy, biologic or hormonal therapy) within 28 days prior to the first dose. 7. Concurrent treatment with an investigational agent or participation in another clinical trial. 8. Previous malignant disease: patients are not eligible for the study if actively being treated of inva-sive cancer other than ovarian cancer. Patients with previous malignant disease other than ovarian cancer who are relapse-free and treatment-free for more than three years may enter this study. Pa-tients with previous history of in-situ carcinoma, stage 1A cervical cancer or non-invasive basal cell and squamous cell skin carcinoma can enter this trial. 9. Active infection including tuberculosis 10. History of a cerebral vascular accident, transient ischemic attack or subarachnoid hemorrhage within the past 6 months. 11. History of clinically significant hemorrhage in the past 3 months. 12. Untreated CNS disease, leptomeningeal disease or cord compression. Subjects with treated dis-ease should have at least 4 weeks of neurologic and radiographic stability and be off steroids for 14 days. 13. Significant cardiovascular disease's. 14. Persistance of clinically relevant therapy related toxicity from previous anticancer therapy (any grade 3-4 toxicity or grade ≥2 neuropathy). 15. Known hypersensitivity to the trial drugs, or to their excipients. 16. Has had prior exposure to IMPs, or any other immunotherapy. 17. Active or prior documented autoimmune or inflammatory disorders 18. For cohorts B and C: Medical condition requiring current systemic anticoagulation, or a history of congenital hypercoagulable condition. Subjects taking aspirin at doses \< 325 mg per day are eli-gible provided that prothrombin time is within the institutional range of normal. Use of local anti-coagulation for port maintenance is permitted
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) | 16 weeks | Disease control rate (DCR) (CR+PR+SD) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) by RECIST v1.1 | 10 months | PFS by RECIST v1.1 |
| PFS by Immune-RECIST | 10 months | PFS by Immune-RECIST |
| Overall survival (OS) | 36 months | Overall survival (OS) |
| Objective response rate | 10 months | Objective response rate according to RECIST v1.1 (ORR) |
| Duration of (Overall) Response (DoR) | 10 months | Duration of (Overall) Response (DoR) |
Countries
Denmark, Finland, Norway
Outcome results
None listed